胺碘酮治疗冠心病室性心律失常的疗效观察

Amiodarone treatment coronary artery disease ventricular arrhythmia effect observation

目的观察胺碘酮治疗冠心病室性心律失常的疗效。方法将120例冠心病室性心律失常患者随机分为治疗组及对照组,对照组口服普罗帕酮,治疗组口服胺碘酮片,比较两组的疗效及不良反应。结果经过治疗,两组患者的室早数、短阵室速数、QTc间期均有显著改善,差异有统计学意义(P<0.05);治疗组的改善情况优于对照组,差异有统计学意义(P<0.05)。两组均未出现严重的不良反应。结论胺碘酮是相对安全的药物,是治疗冠心病合并快速心律失常的首选,尤其患者有器质性心脏病心力衰竭时,可以获得满意的疗效,值得临床推广应用。

Objective Observed Amiodarone treatment coronary artery disease ventricular arrhythmia effect. Methods 120 cases of coronary heart disease hospital ventricular arrhythmias patients were randomly divided into treatment and control groups, control group oral propafenone, treated group oral amiodarone, compared two groups the efficacy and side effects. Results After treatment, two groups of patients the number of premature ventricular contractions, a few short array ventricular tachycardia, QTc interval has significantly improved, there was a significant difference （ P 〈 0. 05 ） ; treatment group improve the situation were better than control group, there was a significant difference （ P 〈 0. 05 ） ; no serious side effects. Conclusion Amiodarone is a relatively safe drug, is the first choice of treatment coronary heart disease, in particular, there are organic heart failure, can be satisfied with the effect should be applied.